Ads
related to: merck- Cell Therapy Production
Cell Therapy Manufacturing Services
From Clinical To Commercial
- AAV Reference Standards
Essential AAV Reference Standards
Full & Empty Capsids of 6 Serotypes
- GMP Retrovirus Services
cGMP-compliant & fully scalable
Viral vector manufacturing
- GMP QC Services
Viral Vector & Plasmid Assays
Quality, Sterility & Potency
- Cell Therapy Production
SCBN.org has been visited by 10K+ users in the past month
Search results
Merck to Acquire EyeBio for $1.3 Billion
Morningstar· 9 hours agoBy Adriano Marchese Merck has agreed to acquire clinical-stage ophthalmology biotech company EyeBio for a $1.3 billion, the two companies said Wednesday. The Wall Street Journal ...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports By Reuters
Investing.com· 18 hours agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to...
Fed official's blunt warning resets rate cut chances
TheStreet via Yahoo Finance· 9 hours agoThe biggest Dow winners were Home Depot (HD) and Intel (INTC) , up 1.1% each. The laggards were health-related: Amgen (AMGN) and Merck (MRK) , down about...
Dow Jones Sells Off 400 Points Ahead Of Fed Report; Nvidia Falls From Record Highs
Investor's Business Daily· 6 hours agoStock Market Today: Best Stocks To Watch Monday.com, Netflix and Crocs — plus Dow Jones components...
Merck stock climbs as breast cancer Phase 3 trial data meets endpoint By Investing.com
Investing.com· 1 day agoMerck & Co (NYSE:MRK) announced on Tuesday that its phase 3 KEYNOTE-522 trial evaluating Keytuda...
Merck nears $1.3 bln takeover of Eyebiotech- WSJ By Investing.com
Investing.com· 18 hours agoMerck nears $1.3 bln takeover of Eyebiotech- WSJ
Merck Announces Third-Quarter 2024 Dividend
Morningstar· 1 day agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of ...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
AOL· 18 hours agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations ...
Exclusive | Merck Nears $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 19 hours agoSuch an acquisition would steer a company known for its cancer immunotherapy, Keytruda, into the...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga· 1 day agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
